{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:54:32Z","timestamp":1794491672026,"version":"4.9.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MicroRNAs (miRNAs) have emerged as pivotal regulators in cancer biology, influencing tumorigenesis, progression, and resistance to therapy. Their ability to modulate multiple oncogenic and tumor-suppressive pathways positions them as promising therapeutic tools or targets. This review examines the dual role of miRNAs in solid and hematological malignancies, starting from their dysregulation in various cancer types. Therapeutic approaches, including miRNA replacement and inhibition strategies, are discussed alongside innovative delivery systems such as lipid nanoparticles and exosomes. Despite their transformative potential, challenges persist, including off-target effects, immune activation, and delivery inefficiencies. Recent clinical trials demonstrate both progress and hurdles, underscoring the need for advanced strategies to optimize specificity and minimize toxicity. This review provides an updated comprehensive overview of the current landscape of miRNA-based therapies under early clinical investigation and explores future directions for integrating these approaches into precision oncology.<\/jats:p>","DOI":"10.1186\/s13046-025-03391-x","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T01:45:03Z","timestamp":1745199903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":236,"title":["MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications"],"prefix":"10.1186","volume":"44","author":[{"given":"Maria Teresa","family":"Di Martino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"1","key":"3391_CR1","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3391_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3391_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13046-023-02752-8","volume":"42","author":"G Blandino","year":"2023","unstructured":"Blandino G, Dinami R, Marcia M, Anastasiadou E, Ryan BM, Palcau AC, Fattore L, Regazzo G, Sestito R, Loria R, et al. The new world of RNA diagnostics and therapeutics. J Exp Clin Cancer Res. 2023;42(1):189.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"3391_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrg1379","volume":"5","author":"L He","year":"2004","unstructured":"He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522\u201331.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"3391_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","volume":"20","author":"J Hayes","year":"2014","unstructured":"Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460\u20139.","journal-title":"Trends Mol Med"},{"issue":"10","key":"3391_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrd3179","volume":"9","author":"R Garzon","year":"2010","unstructured":"Garzon R, Marcucci G, Croce CM. Targeting MicroRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775\u201389.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3391_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203\u201322.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"3391_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857\u201366.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3391_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/clpt.2012.192","volume":"93","author":"SP Nana-Sinkam","year":"2013","unstructured":"Nana-Sinkam SP, Croce CM. Clinical applications for MicroRNAs in cancer. Clin Pharmacol Ther. 2013;93(1):98\u2013104.","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"3391_CR10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.febslet.2010.08.009","volume":"585","author":"SA Melo","year":"2011","unstructured":"Melo SA, Esteller M. Dysregulation of MicroRNAs in cancer: playing with fire. FEBS Lett. 2011;585(13):2087\u201399.","journal-title":"FEBS Lett"},{"issue":"1","key":"3391_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1423-0127-19-90","volume":"19","author":"PS Chen","year":"2012","unstructured":"Chen PS, Su JL, Hung MC. Dysregulation of MicroRNAs in cancer. J Biomed Sci. 2012;19(1):90.","journal-title":"J Biomed Sci"},{"issue":"3","key":"3391_CR12","first-page":"2155","volume":"19","author":"X Zhang","year":"2020","unstructured":"Zhang X, Liu C, Li H, Guo L. Effects of miR-21 on proliferation and apoptosis of WT cells via PTEN\/Akt pathway. Exp Ther Med. 2020;19(3):2155\u201360.","journal-title":"Exp Ther Med"},{"key":"3391_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.omtn.2022.02.005","volume":"27","author":"MT Di Martino","year":"2022","unstructured":"Di Martino MT, Arbitrio M, Caracciolo D, Cordua A, Cuomo O, Grillone K, Riillo C, Carida G, Scionti F, Labanca C, et al. miR-221\/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review. Mol Ther Nucleic Acids. 2022;27:1191\u2013224.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"3391_CR14","doi-asserted-by":"publisher","first-page":"102221","DOI":"10.1016\/j.omtn.2024.102221","volume":"35","author":"A Ali","year":"2024","unstructured":"Ali A, Grillone K, Ascrizzi S, Carida G, Fiorillo L, Ciliberto D, Staropoli N, Tagliaferri P, Tassone P, Di Martino MT. LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation. Mol Ther Nucleic Acids. 2024;35(2):102221.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"3391_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1517\/14728222.2016.1164693","volume":"20","author":"MT Di Martino","year":"2016","unstructured":"Di Martino MT, Rossi M, Caracciolo D, Gulla A, Tagliaferri P, Tassone P. Mir-221\/222 are promising targets for innovative anticancer therapy. Expert Opin Ther Targets. 2016;20(9):1099\u2013108.","journal-title":"Expert Opin Ther Targets"},{"issue":"43","key":"3391_CR16","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1038\/onc.2008.178","volume":"27","author":"F Fornari","year":"2008","unstructured":"Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, et al. MiR-221 controls CDKN1C\/p57 and CDKN1B\/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27(43):5651\u201361.","journal-title":"Oncogene"},{"key":"3391_CR17","doi-asserted-by":"crossref","unstructured":"Wu J, Zhu Y, Liu D, Cong Q, Bai C. Biological functions and potential mechanisms of miR\u2013143\u20133p in cancers (Review). Oncol Rep 2024, 52(3).","DOI":"10.3892\/or.2024.8772"},{"key":"3391_CR18","doi-asserted-by":"publisher","first-page":"154290","DOI":"10.1016\/j.prp.2022.154290","volume":"242","author":"N Mozammel","year":"2023","unstructured":"Mozammel N, Amini M, Baradaran B, Mahdavi SZB, Hosseini SS, Mokhtarzadeh A. The function of miR-145 in colorectal cancer progression; an updated review on related signaling pathways. Pathol Res Pract. 2023;242:154290.","journal-title":"Pathol Res Pract"},{"issue":"10","key":"3391_CR19","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1073\/pnas.0712321105","volume":"105","author":"MS Kumar","year":"2008","unstructured":"Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T. Suppression of non-small cell lung tumor development by the let-7 MicroRNA family. Proc Natl Acad Sci U S A. 2008;105(10):3903\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3391_CR20","doi-asserted-by":"publisher","first-page":"154631","DOI":"10.1016\/j.prp.2023.154631","volume":"248","author":"AT Jalil","year":"2023","unstructured":"Jalil AT, Abdulhadi MA, Al-Ameer LR, Abbas HA, Merza MS, Zabibah RS, Fadhil AA. The emerging role of microRNA-126 as a potential therapeutic target in cancer: a comprehensive review. Pathol Res Pract. 2023;248:154631.","journal-title":"Pathol Res Pract"},{"issue":"10","key":"3391_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/abbs\/gmt073","volume":"45","author":"K Huang","year":"2013","unstructured":"Huang K, Dong S, Li W, Xie Z. The expression and regulation of microRNA-125b in cancers. Acta Biochim Biophys Sin (Shanghai). 2013;45(10):803\u20135.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"1","key":"3391_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13046-019-1059-5","volume":"38","author":"L Zhang","year":"2019","unstructured":"Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019;38(1):53.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"3391_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2013.04.002","volume":"27","author":"CH Lawrie","year":"2013","unstructured":"Lawrie CH. MicroRNAs in hematological malignancies. Blood Rev. 2013;27(3):143\u201354.","journal-title":"Blood Rev"},{"issue":"8","key":"3391_CR24","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","volume":"19","author":"E Leone","year":"2013","unstructured":"Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gulla A, Rossi M, Neri A, Giordano A, Munshi NC, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013;19(8):2096\u2013106.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3391_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.18632\/oncotarget.820","volume":"4","author":"MT Di Martino","year":"2013","unstructured":"Di Martino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, et al. In vitro and in vivo anti-tumor activity of miR-221\/222 inhibitors in multiple myeloma. Oncotarget. 2013;4(2):242\u201355.","journal-title":"Oncotarget"},{"issue":"23","key":"3391_CR26","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.4161\/cc.26585","volume":"12","author":"N Amodio","year":"2013","unstructured":"Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D\u2019Aquila P, Di Martino MT, Calimeri T, Rossi M, Lionetti M, et al. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 2013;12(23):3650\u201362.","journal-title":"Cell Cycle"},{"issue":"22","key":"3391_CR27","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","volume":"18","author":"MT Di Martino","year":"2012","unstructured":"Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gulla A, Conforti F, Morelli E, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012;18(22):6260\u201370.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3391_CR28","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3892\/etm.2021.10567","volume":"22","author":"L Zhang","year":"2021","unstructured":"Zhang L, Bu Z, Shen J, Shang L, Chen Y, Zhang P, Wang Y. MicroRNA-221 regulates cell activity and apoptosis in acute lymphoblastic leukemia via regulating PTEN. Exp Ther Med. 2021;22(4):1133.","journal-title":"Exp Ther Med"},{"key":"3391_CR29","doi-asserted-by":"crossref","unstructured":"Mendiola-Soto DK, Barcenas-Lopez DA, Perez-Amado CJ, Cruz-Miranda GM, Mejia-Arangure JM, Ramirez-Bello J, Hidalgo-Miranda A, Jimenez-Morales S. MiRNAs in hematopoiesis and acute lymphoblastic leukemia. Int J Mol Sci 2023, 24(6).","DOI":"10.3390\/ijms24065436"},{"issue":"1","key":"3391_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/16078454.2020.1860187","volume":"26","author":"C Liang","year":"2021","unstructured":"Liang C, Li Y, Wang LN, Zhang XL, Luo JS, Peng CJ, Tang WY, Huang LB, Tang YL, Luo XQ. Up-regulated miR-155 is associated with poor prognosis in childhood acute lymphoblastic leukemia and promotes cell proliferation targeting ZNF238. Hematology. 2021;26(1):16\u201325.","journal-title":"Hematology"},{"issue":"4","key":"3391_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.leukres.2015.01.010","volume":"39","author":"L Verduci","year":"2015","unstructured":"Verduci L, Azzalin G, Gioiosa S, Carissimi C, Laudadio I, Fulci V, Macino G. microRNA-181a enhances cell proliferation in acute lymphoblastic leukemia by targeting EGR1. Leuk Res. 2015;39(4):479\u201385.","journal-title":"Leuk Res"},{"issue":"6","key":"3391_CR32","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood-2007-07-098749","volume":"111","author":"R Garzon","year":"2008","unstructured":"Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183\u20139.","journal-title":"Blood"},{"issue":"4","key":"3391_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3892\/br.2016.747","volume":"5","author":"YH Feng","year":"2016","unstructured":"Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer. Biomed Rep. 2016;5(4):395\u2013402.","journal-title":"Biomed Rep"},{"key":"3391_CR34","doi-asserted-by":"publisher","first-page":"117727191880684","DOI":"10.1177\/1177271918806840","volume":"13","author":"C Sole","year":"2018","unstructured":"Sole C, Arnaiz E, Lawrie CH. MicroRNAs as biomarkers of B-cell lymphoma. Biomark Insights. 2018;13:1177271918806840.","journal-title":"Biomark Insights"},{"issue":"24","key":"3391_CR35","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2217\/bmm-2023-0575","volume":"17","author":"M Parsa-Kondelaji","year":"2023","unstructured":"Parsa-Kondelaji M, Musavi M, Barzegar F, Abbasian N, Rostami M, M RS, Modi SSH, Nikfar M. A AM-B: dysregulation of MiRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review. Biomark Med. 2023;17(24):1021\u20139.","journal-title":"Biomark Med"},{"issue":"7043","key":"3391_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nature03702","volume":"435","author":"J Lu","year":"2005","unstructured":"Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834\u20138.","journal-title":"Nature"},{"issue":"7","key":"3391_CR37","doi-asserted-by":"publisher","first-page":"838","DOI":"10.2174\/156800912802429355","volume":"12","author":"P Tagliaferri","year":"2012","unstructured":"Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A, Tassone P. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets. 2012;12(7):838\u201346.","journal-title":"Curr Cancer Drug Targets"},{"issue":"Suppl 1","key":"3391_CR38","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1517\/14712598.2013.796356","volume":"13","author":"N Amodio","year":"2013","unstructured":"Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther. 2013;13(Suppl 1):S125\u2013137.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"3391_CR39","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/17474086.2018.1517041","volume":"11","author":"D Caracciolo","year":"2018","unstructured":"Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P. The potential role of MiRNAs in multiple myeloma therapy. Expert Rev Hematol. 2018;11(10):793\u2013803.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"3391_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13046-020-01622-x","volume":"39","author":"K Grillone","year":"2020","unstructured":"Grillone K, Riillo C, Scionti F, Rocca R, Tradigo G, Guzzi PH, Alcaro S, Di Martino MT, Tagliaferri P, Tassone P. Non-coding RNAs in cancer: platforms and strategies for investigating the genomic dark matter. J Exp Clin Cancer Res. 2020;39(1):117.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"3391_CR41","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/onc.2009.445","volume":"29","author":"P Trang","year":"2010","unstructured":"Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, et al. Regression of murine lung tumors by the let-7 MicroRNA. Oncogene. 2010;29(11):1580\u20137.","journal-title":"Oncogene"},{"key":"3391_CR42","doi-asserted-by":"publisher","first-page":"217365","DOI":"10.1155\/2014\/217365","volume":"2014","author":"I Scognamiglio","year":"2014","unstructured":"Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gulla A, Gallo Cantafio ME, Misso G, Tagliaferri P, Tassone P, et al. Transferrin-conjugated snalps encapsulating 2\u2019-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int. 2014;2014:217365.","journal-title":"Biomed Res Int"},{"issue":"2","key":"3391_CR43","doi-asserted-by":"publisher","first-page":"e90005","DOI":"10.1371\/journal.pone.0090005","volume":"9","author":"MT Di Martino","year":"2014","unstructured":"Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gulla A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, et al. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS ONE. 2014;9(2):e90005.","journal-title":"PLoS ONE"},{"issue":"4","key":"3391_CR44","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/leu.2017.336","volume":"32","author":"C Botta","year":"2018","unstructured":"Botta C, Cuce M, Pitari MR, Caracciolo D, Gulla A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME, Prabhala R, et al. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia. 2018;32(4):1003\u201315.","journal-title":"Leukemia"},{"issue":"7","key":"3391_CR45","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/jcp.24306","volume":"228","author":"M Rossi","year":"2013","unstructured":"Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolino FM, Del Giudice T, Iuliano E, et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 2013;228(7):1506\u201315.","journal-title":"J Cell Physiol"},{"issue":"11","key":"3391_CR46","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1038\/cddis.2012.175","volume":"3","author":"N Amodio","year":"2012","unstructured":"Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gulla AM, Pitari MR, Conforti F, Rossi M, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012;3(11):e436.","journal-title":"Cell Death Dis"},{"issue":"10","key":"3391_CR47","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.18632\/oncotarget.675","volume":"3","author":"N Amodio","year":"2012","unstructured":"Amodio N, Leotta M, Bellizzi D, Di Martino MT, D\u2019Aquila P, Lionetti M, Fabiani F, Leone E, Gulla AM, Passarino G, et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget. 2012;3(10):1246\u201358.","journal-title":"Oncotarget"},{"issue":"1","key":"3391_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41598-021-04065-2","volume":"12","author":"Y Kimura","year":"2022","unstructured":"Kimura Y, Ohzawa H, Miyato H, Kaneko Y, Saito A, Takahashi K, Tojo M, Yamaguchi H, Kurashina K, Saito S, et al. MiR-29b May suppresses peritoneal metastases through Inhibition of the mesothelial-mesenchymal transition (MMT) of human peritoneal mesothelial cells. Sci Rep. 2022;12(1):205.","journal-title":"Sci Rep"},{"key":"3391_CR49","doi-asserted-by":"crossref","unstructured":"Liu YL, Yang WH, Chen BY, Nie J, Su ZR, Zheng JN, Gong ST, Chen JN, Jiang D, Li Y. miR\u201329b suppresses proliferation and induces apoptosis of hepatocellular carcinoma Ascites H22 cells via regulating TGF\u2013beta1 and p53 signaling pathway. Int J Mol Med 2021, 48(2).","DOI":"10.3892\/ijmm.2021.4990"},{"issue":"3","key":"3391_CR50","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s41375-020-0947-1","volume":"35","author":"M Rossi","year":"2021","unstructured":"Rossi M, Altomare E, Botta C, Gallo Cantafio ME, Sarvide S, Caracciolo D, Riillo C, Gaspari M, Taverna D, Conforti F, et al. miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. Leukemia. 2021;35(3):823\u201334.","journal-title":"Leukemia"},{"issue":"29","key":"3391_CR51","doi-asserted-by":"publisher","first-page":"27343","DOI":"10.18632\/oncotarget.4398","volume":"6","author":"MR Pitari","year":"2015","unstructured":"Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, Gulla A, Caracciolo D, Di Martino MT, Arbitrio M, et al. Inhibition of miR-21 restores RANKL\/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. Oncotarget. 2015;6(29):27343\u201358.","journal-title":"Oncotarget"},{"key":"3391_CR52","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12935-020-01394-6","volume":"20","author":"SH Javanmard","year":"2020","unstructured":"Javanmard SH, Vaseghi G, Ghasemi A, Rafiee L, Ferns GA, Esfahani HN, Nedaeinia R. Therapeutic Inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies. Cancer Cell Int. 2020;20:384.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"3391_CR53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-023-01468-8","volume":"16","author":"P Tassone","year":"2023","unstructured":"Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci B, Salvino A, et al. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study. J Hematol Oncol. 2023;16(1):68.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3391_CR54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13046-018-0767-6","volume":"37","author":"MF Santolla","year":"2018","unstructured":"Santolla MF, Lappano R, Cirillo F, Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri P, Di Martino MT, Maggiolini M, et al. miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20\/c-Rel\/CTGF signaling. J Exp Clin Cancer Res. 2018;37(1):94.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"3391_CR55","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1158\/1078-0432.CCR-15-0489","volume":"22","author":"A Gulla","year":"2016","unstructured":"Gulla A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, et al. A 13 Mer LNA-i-miR-221 inhibitor restores drug sensitivity in Melphalan-Refractory multiple myeloma cells. Clin Cancer Res. 2016;22(5):1222\u201333.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3391_CR56","doi-asserted-by":"publisher","first-page":"e89659","DOI":"10.1371\/journal.pone.0089659","volume":"9","author":"MT Di Martino","year":"2014","unstructured":"Di Martino MT, Gulla A, Gallo Cantafio ME, Altomare E, Amodio N, Leone E, Morelli E, Lio SG, Caracciolo D, Rossi M, et al. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS ONE. 2014;9(2):e89659.","journal-title":"PLoS ONE"},{"issue":"3","key":"3391_CR57","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/hep.25747","volume":"56","author":"E Callegari","year":"2012","unstructured":"Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, Giacomelli L, D\u2019Abundo L, Ferracin M, Bassi C, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse Transgenic model. Hepatology. 2012;56(3):1025\u201333.","journal-title":"Hepatology"},{"issue":"10","key":"3391_CR58","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1182\/blood-2018-03-836601","volume":"132","author":"E Morelli","year":"2018","unstructured":"Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gulla A, et al. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood. 2018;132(10):1050\u201363.","journal-title":"Blood"},{"key":"3391_CR59","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3389\/fgene.2019.01278","volume":"10","author":"S Li","year":"2019","unstructured":"Li S, Li Q, Lu J, Zhao Q, Li D, Shen L, Wang Z, Liu J, Xie D, Cho WC, et al. Targeted Inhibition of miR-221\/222 promotes cell sensitivity to cisplatin in Triple-Negative breast Cancer MDA-MB-231 cells. Front Genet. 2019;10:1278.","journal-title":"Front Genet"},{"issue":"4","key":"3391_CR60","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/nat.2020.0914","volume":"31","author":"N Arghiani","year":"2021","unstructured":"Arghiani N, Matin MM. miR-21: A key small molecule with great effects in combination Cancer therapy. Nucleic Acid Ther. 2021;31(4):271\u201383.","journal-title":"Nucleic Acid Ther"},{"issue":"22","key":"3391_CR61","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.2174\/1381612821666150531164540","volume":"21","author":"HY Xue","year":"2015","unstructured":"Xue HY, Guo P, Wen WC, Wong HL. Lipid-Based nanocarriers for RNA delivery. Curr Pharm Des. 2015;21(22):3140\u20137.","journal-title":"Curr Pharm Des"},{"key":"3391_CR62","doi-asserted-by":"crossref","unstructured":"Yang J, Zeng H, Luo Y, Chen Y, Wang M, Wu C, Hu P. Recent applications of PLGA in drug delivery systems. Polym (Basel) 2024, 16(18).","DOI":"10.3390\/polym16182606"},{"key":"3391_CR63","doi-asserted-by":"publisher","first-page":"1254356","DOI":"10.3389\/fbioe.2023.1254356","volume":"11","author":"H Chen","year":"2023","unstructured":"Chen H, Yao H, Chi J, Li C, Liu Y, Yang J, Yu J, Wang J, Ruan Y, Pi J, et al. Engineered exosomes as drug and RNA co-delivery system: new hope for enhanced therapeutics? Front Bioeng Biotechnol. 2023;11:1254356.","journal-title":"Front Bioeng Biotechnol"},{"key":"3391_CR64","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jconrel.2022.05.027","volume":"347","author":"I Kimiz-Gebologlu","year":"2022","unstructured":"Kimiz-Gebologlu I, Oncel SS. Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Control Release. 2022;347:533\u201343.","journal-title":"J Control Release"},{"issue":"5","key":"3391_CR65","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/cas.14359","volume":"111","author":"H Ogawa","year":"2020","unstructured":"Ogawa H, Nakashiro KI, Tokuzen N, Kuribayashi N, Goda H, Uchida D. MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma. Cancer Sci. 2020;111(5):1645\u201351.","journal-title":"Cancer Sci"},{"issue":"3","key":"3391_CR66","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1159\/000460510","volume":"41","author":"HX Chen","year":"2017","unstructured":"Chen HX, Xu XX, Tan BZ, Zhang Z, Zhou XD. MicroRNA-29b inhibits angiogenesis by targeting VEGFA through the MAPK\/ERK and PI3K\/Akt signaling pathways in endometrial carcinoma. Cell Physiol Biochem. 2017;41(3):933\u201346.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"3391_CR67","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13046-021-01865-2","volume":"40","author":"X Wu","year":"2021","unstructured":"Wu X, Cheng YL, Matthen M, Yoon A, Schwartz GK, Bala S, Taylor AM, Momen-Heravi F. Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion. J Exp Clin Cancer Res. 2021;40(1):70.","journal-title":"J Exp Clin Cancer Res"},{"key":"3391_CR68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.omtn.2020.01.036","volume":"20","author":"MT Di Martino","year":"2020","unstructured":"Di Martino MT, Arbitrio M, Caracciolo D, Scionti F, Tagliaferri P, Tassone P. Dose-Finding study and pharmacokinetics profile of the novel 13-Mer antisense miR-221 inhibitor in Sprague-Dawley rats. Mol Ther Nucleic Acids. 2020;20:73\u201385.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3391_CR69","doi-asserted-by":"publisher","first-page":"100197","DOI":"10.1016\/j.crphar.2024.100197","volume":"7","author":"M Fonsi","year":"2024","unstructured":"Fonsi M, Fulbert J, Billat PA, Arbitrio M, Tagliaferri P, Tassone P, Di Martino MT. Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation. Curr Res Pharmacol Drug Discov. 2024;7:100197.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"3","key":"3391_CR70","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2020.05.215","volume":"529","author":"K Kim","year":"2020","unstructured":"Kim K, Kim HH, Lee CH, Kim S, Cheon GJ, Kang KW, Chung JK, Youn H. Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer. Biochem Biophys Res Commun. 2020;529(3):707\u201313.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"3391_CR71","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/bit.28603","volume":"121","author":"G Behrouzian Fard","year":"2024","unstructured":"Behrouzian Fard G, Ahmadi MH, Gholamin M, Amirfakhrian R, Saberi Teimourian E, Karimi MA, Hosseini Bafghi M. CRISPR-Cas9 technology: as an efficient genome modification tool in the cancer diagnosis and treatment. Biotechnol Bioeng. 2024;121(2):472\u201388.","journal-title":"Biotechnol Bioeng"},{"issue":"11","key":"3391_CR72","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1261\/rna.2414110","volume":"16","author":"MS Ebert","year":"2010","unstructured":"Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA. 2010;16(11):2043\u201350.","journal-title":"RNA"},{"issue":"1","key":"3391_CR73","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0034-1397352","volume":"35","author":"J Xie","year":"2015","unstructured":"Xie J, Burt DR, Gao G. Adeno-associated virus-mediated MicroRNA delivery and therapeutics. Semin Liver Dis. 2015;35(1):81\u20138.","journal-title":"Semin Liver Dis"},{"key":"3391_CR74","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jare.2020.08.012","volume":"28","author":"C Chakraborty","year":"2021","unstructured":"Chakraborty C, Sharma AR, Sharma G, Lee SS. Therapeutic advances of MiRNAs: A preclinical and clinical update. J Adv Res. 2021;28:127\u201338.","journal-title":"J Adv Res"},{"issue":"7","key":"3391_CR75","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1021\/ar200253u","volume":"45","author":"Z Li","year":"2012","unstructured":"Li Z, Rana TM. Molecular mechanisms of RNA-triggered gene Silencing machineries. Acc Chem Res. 2012;45(7):1122\u201331.","journal-title":"Acc Chem Res"},{"issue":"7291","key":"3391_CR76","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature08956","volume":"464","author":"ME Davis","year":"2010","unstructured":"Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered SiRNA via targeted nanoparticles. Nature. 2010;464(7291):1067\u201370.","journal-title":"Nature"},{"issue":"5","key":"3391_CR77","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4155\/tde-2016-0006","volume":"7","author":"AM Reichmuth","year":"2016","unstructured":"Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319\u201334.","journal-title":"Ther Deliv"},{"issue":"Suppl 1","key":"3391_CR78","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","volume":"11","author":"N Bessis","year":"2004","unstructured":"Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004;11(Suppl 1):S10\u201317.","journal-title":"Gene Ther"},{"issue":"2","key":"3391_CR79","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/oli.2009.0180","volume":"19","author":"M Robbins","year":"2009","unstructured":"Robbins M, Judge A, MacLachlan I. SiRNA and innate immunity. Oligonucleotides. 2009;19(2):89\u2013102.","journal-title":"Oligonucleotides"},{"issue":"2\u20133","key":"3391_CR80","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","volume":"216","author":"J Szebeni","year":"2005","unstructured":"Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216(2\u20133):106\u201321.","journal-title":"Toxicology"},{"issue":"39","key":"3391_CR81","doi-asserted-by":"publisher","first-page":"15549","DOI":"10.1073\/pnas.0707461104","volume":"104","author":"DW Bartlett","year":"2007","unstructured":"Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of SiRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007;104(39):15549\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3391_CR82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cotox.2017.11.011","volume":"10","author":"NB Alsaleh","year":"2018","unstructured":"Alsaleh NB, Brown JM. Immune responses to engineered nanomaterials: current Understanding and challenges. Curr Opin Toxicol. 2018;10:8\u201314.","journal-title":"Curr Opin Toxicol"},{"issue":"9","key":"3391_CR83","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1038\/mtna.2015.23","volume":"4","author":"JK Lam","year":"2015","unstructured":"Lam JK, Chow MY, Zhang Y, Leung SW. SiRNA versus MiRNA as therapeutics for gene Silencing. Mol Ther Nucleic Acids. 2015;4(9):e252.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"18","key":"3391_CR84","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","volume":"70","author":"AG Bader","year":"2010","unstructured":"Bader AG, Brown D, Winkler M. The promise of MicroRNA replacement therapy. Cancer Res. 2010;70(18):7027\u201330.","journal-title":"Cancer Res"},{"issue":"1","key":"3391_CR85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0163-7258(98)00020-5","volume":"80","author":"PD Robbins","year":"1998","unstructured":"Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther. 1998;80(1):35\u201347.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"3391_CR86","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrd4363","volume":"13","author":"S Mitragotri","year":"2014","unstructured":"Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655\u201372.","journal-title":"Nat Rev Drug Discov"},{"key":"3391_CR87","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","volume":"313","author":"SWL Lee","year":"2019","unstructured":"Lee SWL, Paoletti C, Campisi M, Osaki T, Adriani G, Kamm RD, Mattu C, Chiono V. MicroRNA delivery through nanoparticles. J Control Release. 2019;313:80\u201395.","journal-title":"J Control Release"},{"issue":"7","key":"3391_CR88","doi-asserted-by":"publisher","first-page":"851","DOI":"10.15252\/emmm.201100899","volume":"6","author":"E van Rooij","year":"2014","unstructured":"van Rooij E, Kauppinen S. Development of MicroRNA therapeutics is coming of age. EMBO Mol Med. 2014;6(7):851\u201364.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"3391_CR89","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhu L, Wang X, Jin H. RNA-based therapeutics: an overview and prospectus. Cell Death Dis. 2022;13(7):644.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3391_CR90","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11427-022-2171-2","volume":"66","author":"C Zhang","year":"2023","unstructured":"Zhang C, Zhang B. RNA therapeutics: updates and future potential. Sci China Life Sci. 2023;66(1):12\u201330.","journal-title":"Sci China Life Sci"},{"key":"3391_CR91","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","volume":"81","author":"Y Chen","year":"2015","unstructured":"Chen Y, Gao DY, Huang L. In vivo delivery of MiRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128\u201341.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3391_CR92","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","volume":"35","author":"MS Beg","year":"2017","unstructured":"Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35(2):180\u20138.","journal-title":"Invest New Drugs"},{"issue":"11","key":"3391_CR93","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630\u20137.","journal-title":"Br J Cancer"},{"issue":"10","key":"3391_CR94","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","volume":"18","author":"N van Zandwijk","year":"2017","unstructured":"van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386\u201396.","journal-title":"Lancet Oncol"},{"key":"3391_CR95","doi-asserted-by":"publisher","first-page":"470","DOI":"10.18632\/oncotarget.28608","volume":"15","author":"CL Duurland","year":"2024","unstructured":"Duurland CL, Gunst T, Boer HCD, Bosch M, Telford BJ, Vos RM, Xie X, Zang M, Wang F, Shao Y, et al. INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of Immunogenic cell death. Oncotarget. 2024;15:470\u201385.","journal-title":"Oncotarget"},{"issue":"7","key":"3391_CR96","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41375-023-01937-6","volume":"37","author":"H Issa","year":"2023","unstructured":"Issa H, Bhayadia R, Winkler R, Swart LE, Heckl D, Klusmann JH. Preclinical testing of miRNA-193b-3p mimic in acute myeloid leukemias. Leukemia. 2023;37(7):1583\u20137.","journal-title":"Leukemia"},{"issue":"3","key":"3391_CR97","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjh.15547","volume":"183","author":"AG Seto","year":"2018","unstructured":"Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, Jackson AL. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018;183(3):428\u201344.","journal-title":"Br J Haematol"},{"issue":"4","key":"3391_CR98","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","volume":"27","author":"E Anastasiadou","year":"2021","unstructured":"Anastasiadou E, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC, Pestano L, Marchese C, Avigan D, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo. Clin Cancer Res. 2021;27(4):1139\u201349.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3391_CR99","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2215\/CJN.0000000000000458","volume":"19","author":"DP Gale","year":"2024","unstructured":"Gale DP, Gross O, Wang F, Esteban de la Rosa RJ, Hall M, Sayer JA, Appel G, Hariri A, Liu S, Maski M, et al. A randomized controlled clinical trial testing effects of Lademirsen on kidney function decline in adults with Alport syndrome. Clin J Am Soc Nephrol. 2024;19(8):995\u20131004.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"3391_CR100","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-025-01248-2","volume":"15","author":"K Soureas","year":"2025","unstructured":"Soureas K, Malandrakis P, Papadimitriou MA, Minopoulos C, Ntanasis-Stathopoulos I, Liacos CI, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, et al. Refining precision prognostics in multiple myeloma: loss of miR-221\/222 cluster in CD138\u2009+\u2009plasma cells results in short-term progression and worse treatment outcome. Blood Cancer J. 2025;15(1):41.","journal-title":"Blood Cancer J"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03391-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03391-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03391-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:03:05Z","timestamp":1771948985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03391-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3391"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03391-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: author, Maria Teresa Di Martino, was incorrectly tagged.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agree to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}